蛋白質藥若量產 補生技業缺口 2013/10/02 20:29:53 （中央社記者林孟汝台北2013年10月2日電）行政院科技會報執行秘書吳明機今天表示，台灣生技新藥產業鏈，目前仍未補足蛋白質藥物量產工廠缺口，一旦關鍵能量建置完成，就可發揮如半導體中晶圓代工的產業領導角色。行政院2013年生技產業策略會議7日起將在台北福華飯店登場，以「健康智慧生活」為主軸，聚焦「整合醫管實力，發展健康產業」、「創新智慧醫療器材開發」及「生技新藥之利基及策略」3項主題，計有海內外產官學研100多位人士參加。3天會議中，將邀請台北大學董事長李祖德分享台灣生技產業的發展策略，及邀請Lin&Associates全球法規顧問公司總林秋雄、台灣大學校長楊泮池、台灣生技整合育成中心首席顧問蘇懷仁、美國Tesoro公司董事長楊育民等，發表專題演講。外界擔心兩岸生技產業遊戲規則未制度化，為了搶市場，可能台灣生技產業還沒起飛，就被淘空。吳明機指出，台灣生技新藥產業鏈，目前仍未補足蛋白質藥物量產工廠缺口，日前成立的台康生技等公司就像半導體中的晶圓代工廠台積電，可提供國內生技業者製造及研發服務，加速台灣生技業產值未來呈倍數成長。台康生技成立於去年12月，前身為生技中心的Cgmp生技藥品的先導工廠，該工廠也是國內第一座符合美國FDA規範的cGMP生技藥品先導工廠，目前公司資本額為新台幣5.4億元，其中國發基金約占15%，非常需要創投基金投入。
Patrick Y. Yang Independent Director Director Since December 2010
Former Head of Global Technical Operations for F. Hoffmann-La Roche Ltd.
Tesoro Corporation Committee Membership:Environmental, Health, Safety and Security Committee, Governance Committee
Patrick Yang was elected to Tesoro's Board of Directors in December 2010. From January 2010 to March 2013, he served as Head of Global Technical Operations for F. Hoffmann-La Roche Ltd. where he was responsible for the company's pharmaceutical manufacturing, process development, engineering, quality, regulatory, supply chain and procurement. Before joining Roche, he worked for Genentech, Merck & Co., General Electric and Life Systems, during which time he developed significant experience with pharmaceuticals manufacturing, engineering, technology, and supply chain management. He previously served on the board of TaiMed Biologics. He earned a Bachelor of Science in Engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.
No comments:
Post a Comment